Determining how insulin and the insulin receptor (IR) signaling promote mammary tumor growth and metastases is critical for our understanding of the association between obesity, type 2 diabetes (T2D) and breast cancer. Obesity and T2D are associated with an increased risk of breast cancer metastasis, recurrence, resistance to therapy and cancer-related mortality, particularly in triple negative and HER2 overexpressing cancers. While there are many metabolic changes in these individuals, endogenous hyperinsulinemia is common to obesity and T2D, and has been independently correlated with a worse prognosis in women with breast cancer. Furthermore, increased IR expression and phosphorylation in human breast cancer specimens is associated with a worse prognosis. To determine insulin's effects on mammary tumor growth, we have studied a mouse model of hyperinsulinemia in isolation from obesity and the other metabolic abnormalities associated with obesity. These hyperinsulinemic mice developed larger primary mammary tumors, and more metastases than mice with normal insulin concentrations. We found that these tumors had increased IR phosphorylation in addition to greater expression of c-myc, vimentin, MMP-9 and miR-222. Therefore, we hypothesize that endogenous hyperinsulinemia, signaling through the IR increases the growth and metastases of triple negative and HER2 overexpressing breast cancers by altering their phenotype. In this proposal we aim to: 1. Determine if the insulin receptor is the key receptor mediating the effect of hyperinsulinemia on mammary tumor growth and metastases. 2. Define the molecular mechanisms through which hyperinsulinemia promotes tumor metastases. We will achieve these aims by using two mouse models of hyperinsulinemia, a non-obese mouse model with isolated hyperinsulinemia, and an obese mouse model will hyperinsulinemia and the other metabolic changes that occur in obesity. We will silence the IR in murine and human triple negative breast cancer cell lines. Using a mammary epithelial specific knockout of the IR, we will examine whether the effects of hyperinsulinemia on mammary tumor growth and metastases are mediated through the IR. Secondly, we will examine the effect of hyperinsulinemia and inhibiting IR signaling on the primary tumor phenotype, including mesenchymal markers and the size of the tumor initiating cell population. We will inhibit c-myc to determine if c-myc is a key downstream mediator of insulin action. Finally, we will validate our animal models by studying the correlation between IR phosphorylation and vimentin and c-myc expression in human HER2 overexpressing and triple negative breast cancers. At the conclusion of these studies, we anticipate that we will define many of the mechanisms involved in the effect of hyperinsulinemia on breast cancer progression and metastases. These results will be critical for the development of more appropriate interventions to treat breast (and other) cancers in the increasing number of women with obesity, T2D and the metabolic syndrome.

Public Health Relevance

Obese women and those with Type 2 diabetes who develop breast cancer are more likely to have aggressive cancer, are less likely to respond to treatment and have a greater chance of dying. Through our studies we aim to determine the mechanisms through which high insulin levels and activation of the insulin receptor in tumors increase breast cancer aggression, and thus identify targets for new therapies that may be beneficial particularly in the increasing number of women with obesity and Type 2 Diabetes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA128799-06A1
Application #
8694243
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2007-07-01
Project End
2019-05-31
Budget Start
2014-06-12
Budget End
2015-05-31
Support Year
6
Fiscal Year
2014
Total Cost
$380,225
Indirect Cost
$155,225
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Alikhani, N; Ferguson, R D; Novosyadlyy, R et al. (2013) Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 32:961-7
Gallagher, E J; Fierz, Y; Vijayakumar, A et al. (2012) Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 31:3213-22
Vaitheesvaran, B; LeRoith, D; Kurland, I J (2010) MKR mice have increased dynamic glucose disposal despite metabolic inflexibility, and hepatic and peripheral insulin insensitivity. Diabetologia 53:2224-32
Fierz, Yvonne; Novosyadlyy, Ruslan; Vijayakumar, Archana et al. (2010) Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59:686-93
Cannata, Dara; Lann, Danielle; Wu, Yingjie et al. (2010) Elevated circulating IGF-I promotes mammary gland development and proliferation. Endocrinology 151:5751-61
Fierz, Yvonne; Novosyadlyy, Ruslan; Vijayakumar, Archana et al. (2010) Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer 17:941-51
Vijayakumar, Archana; Novosyadlyy, Ruslan; Wu, Yingjie et al. (2010) Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 20:1-7
Novosyadlyy, R; Vijayakumar, A; Lann, D et al. (2009) Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation. Oncogene 28:3477-86
Wu, Yingjie; Sun, Hui; Yakar, Shoshana et al. (2009) Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology 150:4395-403